EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Rapidly Progressing Bilateral Cataracts during Mirvetuximab Soravtansine Therapy: A Case Series

Connor J Alder, Ashley Ahlbrand, Carolyn K McCourt, Erin G Sieck

Ocular Oncology and Pathology · 21.05.2026 · 1-5

DOI: 10.1159/000552640 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 21.05.2026. Verfasst von Connor J Alder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mirvetuximab soravtansine is an antibody-drug conjugate approved for the treatment of folate receptor alpha-expressing ovarian cancer and is associated with ocular adverse events. Patients treated with mirvetuximab soravtansine often develop moderate to severe keratopathy, requiring topical steroids. Recent studies suggest a higher incidence of cataract formation than initially reported. This case series describes the rapid development of visually significant cataracts in 3 patients receiving mirvetuximab therapy. Case Presentations: Three female patients undergoing treatment with mirvetuximab soravtansine for platinum-resistant serous ovarian cancer experienced significant visual decline after 11, 18, and 19 treatment cycles, in 1 case progressing from 20/25 to counting fingers in both eyes within 10 weeks. All patients had baseline ophthalmic examinations and were treated with prophylactic topical corticosteroids to mitigate corneal complications. Despite standard management, each patient developed bilateral posterior subcapsular cataracts with substantial loss of visual acuity. Patients underwent sequential or same-day bilateral cataract extraction without complication. Postoperatively, all patients regained their baseline vision, and oncologic therapy was continued.

Conclusion

Rapidly progressing posterior subcapsular cataracts may occur in patients receiving prolonged mirvetuximab soravtansine therapy and may reflect drug-related toxicity, steroid exposure, or a synergistic interaction. Given that these patients did not develop cataracts until later cycles, ophthalmologic monitoring may be warranted beyond the duration specified in current treatment protocols. Early recognition and cataract surgery can restore vision without requiring cessation of oncologic therapy.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugateCase seriesMirvetuximabOcular adverse effectsOvarian neoplasmPosterior subcapsular cataractSoravtansine

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.
  • Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USA.

Zitieren

APA

Alder, C. J., Ahlbrand, A., McCourt, C. K., & Sieck, E. G. (2026). Rapidly Progressing Bilateral Cataracts during Mirvetuximab Soravtansine Therapy: A Case Series. Ocular Oncology and Pathology, 1-5. https://doi.org/10.1159/000552640

Vancouver

Alder CJ, Ahlbrand A, McCourt CK, Sieck EG. Rapidly Progressing Bilateral Cataracts during Mirvetuximab Soravtansine Therapy: A Case Series. Ocular Oncology and Pathology. 2026:1-5. doi:10.1159/000552640

BibTeX
@article{Alder2026,
  author = {Alder, Connor J and Ahlbrand, Ashley and McCourt, Carolyn K and Sieck, Erin G},
  title = {Rapidly Progressing Bilateral Cataracts during Mirvetuximab Soravtansine Therapy: A Case Series},
  journal = {Ocular Oncology and Pathology},
  year = {2026},
  pages = {1--5},
  doi = {10.1159/000552640}
}
Kostenlos starten →